Top Stories Wednesday, June 22, 2016 In all the talk of “disruption” and “hacking cancer,” you’d be forgiven for not taking internet billionaire Sean Parker seriously in the life sciences world. But he just got federal backing to run the world’s first-ever CRISPR/Cas9 trial, which could alter the way many diseases, especially cancer, are treated. Monday, July 18, 2016 Swiss cancer major Roche has flubbed a late-stage trial pitting one of its newer drugs against an aging stalwart as it failed to help patients with an aggressive form of blood cancer live longer. Friday, August 5, 2016 After strong positive data from Merck in June for its Keytruda to treat first-line advanced non-small cell lung cancer (NSCLC), now BMS has revealed that its own Opdivo did not meet the primary endpoint in a Phase III trial in the same indication. Tuesday, November 1, 2016 Pfizer is to dump all work on its proprotein convertase subtilisin/kexin type 9 inhibitor (PCSK9i) bococizumab due to weak data and an “evolving treatment and market landscape for lipid-lowering agents.” Wednesday, October 12, 2016 The For Better Science blog has confirmed that a leading cancer researcher has been let go by Pfizer as the U.S. Big Pharma giant initiated a series of science paper retractions after allegations of data manipulation. Thursday, July 7, 2016 Juno Therapeutics had hoped to have a first approval for a candidate next year. But that looks unlikely to happen as the pivotal trial for this lead candidate has been put on hold by the FDA after three patient deaths. Thursday, August 18, 2016 The ongoing patent battle over just who owns the rights to the cutting-edge CRISPR-Cas9 gene editing technology has heated up this week with a new email from a junior scientist putting more confusion over who invented what first. Tuesday, July 19, 2016 Buried deep down in Novartis’ Q2 results out this morning was a previously unknown rejection by the FDA for a copycat version of Amgen’s blockbuster drug Neulasta (pegfilgrastim). Sunday, June 5, 2016 AbbVie got a chance on Sunday to start explaining just why it was inspired to pay a whopping $5.8 billion upfront--with $4 billion reserved for milestones--for Stemcentrx and its overnight cancer drug sensation Rova-T. Friday, May 27, 2016 The FDA handed down a major shock to AstraZeneca yesterday when it rejected its key hyperkalemia drug ZS-9, leaving potential rival Relypsa’s shares to jump in after-hours trading. Resources Presented By: Lenovo Get the stats you need to start down the path to a more secure infrastructure, today. Presented By: Lenovo What's the first step to a better patient experience? The patient experience starts well before the exam room or even reception - it begins as soon as your patients pull into the parking structure. Presented by: DocuSign DocuSign’s eSignature solutions modernize healthcare and life science organizations by eliminating paper and antiquated signature processes while meeting compliance requirements and reducing costs and errors. Presented by: DocuSign The patients who rely on your scientific leadership are expecting more. Presented by: DocuSign The U.S. Department of Justice has collected upwards of $17 billion in settlements from the healthcare industry since 2009, including more than $2 billion from a single life sciences company. Sponsored By: Salesforce Life sciences companies, like many industries today, face new challenges across the board. Read More. Presented By: ISR Reports Make essential outsourced bioprocessing decisions by staying informed of industry outsourcing practices and contract manufacturer usage patterns with ISR’s Bioprocessing Services and Technologies Market Trends and Outsourcing Dynamics report. Presented By: ISR Reports ISR’s Biosimilars in the US Oncology Market (2nd Edition) report provides data and insights from 101 US-based, board-certified oncologists/hematologist oncologists as to their expectations, fears, and aspirations for biosimilars in oncology. Presented By: ISR Reports Pinpoint the information oncologists find most valuable and the best sales channels for delivering specific types of data/information. Presented By: ISR Reports ISR’s Bioprocessing Market Trends and Outsourcing Dynamics: 2016-2021 report provides an overview of the current market dynamics for bioprocessing as well as an outlook on what the marketplace will look like in five years. Presented By: ISR Reports ISR’s CRO Quality Benchmarking – Phase II/III Service Providers (8th Edition) report provides a Consumer Reports-style analysis of Phase II/III CRO service quality from hundreds of users who rated 44 Phase II/III CROs across 26 critical dimensions of quality. Presented by: Patheon Can you avoid a risky trial-and-error approach to find the right path for your poorly soluble molecule by utilizing a CDMO? Download this complimentary Whitepaper to learn more! Presented by: Biotech Primer This 3-part webinar series is specifically geared toward the non-science professional who needs to better understand industry terminology, science, techniques and issues. Sponsored by: Veeva Systems Gartner research on short- and long-term strategies for IDMP compliance. Fierce Innovation Awards: Life Sciences Edition 2016 Application Deadline: Friday, December 2nd Discover the Richness of Latin America November 29–30, 2016 | San Juan, Puerto Rico Immunotherapy: Mapping the Future of Cancer Drug Discovery November 28, 2016 | Munich, Germany 24th International Molecular Medicine Tri-Conference February 19-24, 2017 | Moscone North Convention Center | San Francisco, CA FierceBiotech Executive Breakfast: Deciphering Immuno-Oncology, Trends in Deal-Making and R&D January 10, 2017 | San Francisco, CA | 